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Abstract 
 
FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a 
central role in DNA double-strand type damage responses. Using complementation 
assays and immunoblotting, a consortium of American and European groups 
assigned 29 FA patients from 23 families and 4 additional unrelated patients to 
complementation group FA-D2. This amounts to 3 to 6% of FA patients registered in 
various datasets. Malformations are frequent in FA-D2 patients and hematological 
manifestations appear earlier and progress more rapidly when compared to patients 
from all other FA groups combined, as represented by the International Fanconi 
Anemia Registry, IFAR. FANCD2 is flanked by two pseudogenes. Mutation analysis 
revealed the expected total of 66 mutated alleles, 34 of which result in aberrant 
splicing patterns. Many mutations are recurrent and have ethnic associations and 
shared alleles. There were no biallelic null mutations so that residual FANCD2 
protein of both isotypes was observed in all patients’ cell lines available. These 
analyses suggest that unlike in a knock-out mouse model, total absence of FANCD2 
is not existing in FA-D2 patients due to constraints on viable combinations of 
FANCD2 mutations. Although hypomorphic mutations are involved, the result 
generally is a relatively severe form of FA. 
 
 
Key words: Fanconi anemia; FANCD2; Hypomorphic mutations; Splicing; Residual 
protein 
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Introduction 
Fanconi anemia (FA) is a rare genome instability disorder with the variable presence 
of congenital malformations, progressive bone marrow failure, predisposition to 
malignancies, and cellular hypersensitivity towards DNA-interstrand crosslinking 
(ICL) agents1. There are at least twelve complementation groups (FA-A, B, C, D1, 
D2, E, F, G, I, J, L and M), each of which is associated with biallelic or hemizygous 
mutations in a distinct gene2. To date, eleven of the underlying genes have been 
identified, denoted FANCA, B, C, D1/BRCA2, D2, E, F, G/XRCC9, J/BRIP1, L/PHF9 
and M/HEF3-5. Eight of the FA proteins (FANCA, B, C, E, F, G, L and M) and other 
components assemble in a nuclear complex, the FA core complex, that is required for 
the monoubiquitination of FANCD2 at amino acid residue K5616,7. Monoubiquitination 
occurs in response to DNA damage and during the S phase of the cell cycle7,8. The 
monoubiquitinated FANCD2 isoform (FANCD2-L as opposed to FANCD2-S) is 
targeted to nuclear foci containing proteins such as BRCA1, BRCA2 and RAD51 that 
are involved in DNA damage signaling and recombinational repair9-12. The precise 
role of FANCD2 remains unknown, but FANCD2-deficient DT40 cells show defects in 
homologous recombination-mediated DNA double-strand break (DSB) repair, 
translesion synthesis and gene conversion9,13,14. Therefore, FANCD2 is thought to 
play a central role in the maintenance of genome stability9,14,15. 
The human and murine Fancd2 genes show a higher degree of homology than 
the corresponding Fanca, c, e, f and g genes16. Fancd2 knock-out mice suffer from 
perinatal lethality, microphthalmia and early epithelial cancers17, but it remains 
controversial whether the murine FA-D2 phenotype generally is more severe than the 
corresponding murine knock-outs of the other FA genes17,18. Fancd2 is required for 
survival after DNA damage in C. elegans19, and Fancd2-deficient zebrafish embryos 
display severe developmental defects due to increased apoptosis, underscoring the 
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importance of Fancd2 function during vertebrate ontogenesis20. Finally, knock-down 
of drosophila Fancd2 causes pupal lethality21. In humans, it has been estimated that 
complementation group FA-D2 accounts for less than 1%22 to 3%23 of all FA patients. 
The presence of FANCD2 pseudogenes complicating mutation analysis may explain 
why there has been no other report of human FANCD2 mutations since the original 
description24. As a concerted effort among nine laboratories we present a 
comprehensive mutation profile of the FANCD2 gene. We show that the FA 
phenotype resulting from FANCD2 deficiency is relatively severe and, in contrast to 
all other FA genes, (1) the mutation spectrum of FANCD2 is dominated by splicing 
mutations, and (2) residual FANCD2 protein exists in all tested cell lines from FA-D2 
patients, suggesting lethality of biallelic null mutations. 
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Patients, materials and methods 
 
Diagnostic procedures 
Anti-coagulated peripheral blood and skin biopsy samples were referred to the 
participating laboratories for diagnostic testing. Confirmation of the diagnosis of FA, 
subtyping and mutation analysis were performed with informed consent according to 
the Declaration of Helsinki. The study was approved by the institutional review 
boards of the participating centers. Clinical suspicion of FA was confirmed by the 
detection of cellular hypersensitivity to DNA-crosslinking agents following published 
procedures25-29. In cases with hematopoietic mosaicism, skin fibroblasts were used to 
confirm the diagnosis of FA. 
 
Patient statistics 
A total of 29 fully informative FA-D2 patients (no. 1-29) were included in the present 
genotype-phenotype study. A fetal case (no. 19) and five patients with hematopoietic 
mosaicism (no. 3, 14, 15, 25 and 26) were excluded from clinical follow-up studies. 
Four additional FA-D2 patients (no. 30-33) with incomplete clinical data are not part 
of the phenotype analysis, but results concerning their mutations are shown as 
indicated in the text, tables and figures. 
For calculations of cumulative incidence, the following three end points were 
evaluated: time to bone marrow failure (BMF; hematological onset, defined as cell 
count of at least one lineage constantly below normal range), period from BMF to 
hematological stem cell transplantation (HSCT), and time to HSCT. Kaplan-Meier 
estimates were computed for the length of overall survival. Birth was taken as the 
date of FA onset for all these calculations. Comparisons were made to a body of FA 
patients in the IFAR as previously reported30 by means of log-rank test statistics. 
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Multivariate and competing-risk analyses were not possible due to the limited number 
of informative patients. 
 
Cell culture 
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) were 
established using cyclosporin A as previously described31. All blood-derived cell 
cultures were maintained in RPMI 1640 medium with GlutaMAX (Gibco) 
supplemented with 15% fetal bovine serum (FBS; Sigma). Fibroblast strains were 
established using standard cell culture procedures and propagated in Earle’s MEM 
with GlutaMAX (Gibco) and 15% FBS. All cultures were kept in high humidity 
incubators in an atmosphere of 5% (v/v) CO2 and, in case of fibroblasts, 5% (v/v) O2 
by replacing ambient air with nitrogen32. Mitomycin C (MMC) treatments were for 48 
h at 12 ng/ml (fibroblasts) or 15 ng/ml (LCLs) to cause cell cycle arrest, or for 12 h at 
100 ng/ml to induce FANCD2-L. In some cases, RNA stabilization was achieved by 
cycloheximide (CHX) added to cell cultures at a final concentration of 250 µg/ml 4.5 h 
prior to RNA isolation. 
 
Retroviral complementation 
For construction of the D2-IRES-neo retroviral expression vector S11FD2IN, the D2-
IRES-puro plasmid pMMP-FANCD224 was cut using Sal I. The ends were blunted 
and the fragment containing the FANCD2 ORF was cut out with EcoRI and ligated 
into S11IN cut with BamHI, blunted and also cut again with EcoRI (Figure 1A and 
Supplementary Figure S1). S11 vectors are based on the spleen focus forming virus 
and are derived from the GR plasmid33. Sequencing of the retroviral plasmid 
S11FD2IN revealed three reported polymorphisms in the FANCD2 ORF, c.1122A>G, 
c.1509C>T, c.2141C>T24 and another silent base substitution, c.3978C>T. Stable 
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retroviral packaging cells were generated by infection of PG13 cells and selection in 
G418 (Sigma) as previously described34. In addition, enhanced green fluorescent 
protein (GFP) and FANCA cDNAs were separately cloned into the vector S11IN 
(designated S11EGIN and S11FAIN; Figure 1A) for transduction of the cells under 
study, with EGFP serving to monitor complete selection and FANCA serving as 
negative complementation control. 
Retroviral transduction of cultured cells follwed published protocols35,36. Selection of 
transduced cells was in G418 (Sigma) at a final concentration of 0.8 to 1.2 mg/ml for 
about 10 days. Transduced cells were analyzed for their sensitivity to MMC using 
flow cytometry to assess survival rates and cell cycle arrest36,37. 
 
Immunoblotting 
FANCD2 immunoblotting was performed as first described7 with minor modifications. 
Detection was by the chemiluminescence technique using standard ECL reagent 
(Amersham) or SuperSignalWestFemto (Pierce). 
 
Mutation and haplotype characterization 
Primers used for cDNA amplification are shown in Supplementary Table S1A, those 
additionally used for cDNA sequencing are shown in Supplementary Table S1B. 
A total of 15 large amplicons (superamplicons) that are unique to certain regions 
of the functional FANCD2 gene were generated to serve as templates in place of 
genomic DNA. The primers used for superamplifications and the sizes of the 
superamplicons are shown in Supplementary Table S2A. Genomic primers for the 
amplification of all FANCD2 exons and adjacent intron regions and their sizes are 
displayed in Supplementary Table S2B. Additional genomic mutation-specific primers 
are given in Supplementary Table S2C. 
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For haplotyping, four microsatellite markers in the vicinity up- and downstream of 
FANCD2 on chromosome 3 were studied as detailed in the Supplementary methods. 
Primers used for microsatellite amplifications are specified in Supplementary Table 
S3. 
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Results 
 
Assignment to and frequency of group FA-D2 
Figure 1B-E demonstrates our strategy for the assignment of cultured FA cells to 
group FA-D2. Cell cycle analysis was used to ensure MMC sensitivity by G2 phase 
arrest of the LCLs (Figure 1C, lane 2)27-29, while the apparent absence of FANCD2 
bands on standard exposure immunoblots suggested their belonging to group D2 
(Figure 1B, lane 2)38. Transduction of putative D2 LCLs with FANCD2 cDNA using 
the retroviral vector S11FD2IN restored FANCD2 expression and function as 
reflected by the emergence of both FANCD2 isoforms (FANCD2-S and -L; Figure 1B, 
lanes 3); simultaneously, the MMC sensitivity of transduced cells returned to normal 
control cell levels as evidenced by the reduction of G2 phase cell cycle fractions 
(Figure 1C, lane 3; Figure 1B and C, lanes 1). Transduction of D2 LCLs with GFP or 
FANCA did not result in the restoration of either FANCD2 isoform nor in a 
normalization of G2 phase arrest, as exemplified for FANCA using S11FAIN in Figure 
1B and C, lanes 4. In case of suspected hematopoietic mosaicism, cultured 
fibroblasts were assayed using a corresponding strategy (Figure 1D and E). As 
shown in Supplementary Table S4, only a few patients were assigned to group FA-
D2 by primary mutation analysis, including four affected siblings of four different 
index patients, and an unrelated deceased patient with only DNA available. 
In the North American IFAR collection, of 630 classified FA patients 18 were 
assigned to D2. Within in the period of study, seven fully informative of them could be 
included in the present cohort (no. 19-25); another one is among the four additional 
patients (no. 32). Among the patients referred to the two German labs, 15/243 FA 
patients were D2. These data suggest that the proportion of complementation group 
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D2 among two larger series of FA patients may be more frequent than previously 
reported2,22,23. 
 
Clinical data of FA-D2 patients 
Including, where possible, information from a prenatal case (no. 19), malformations in 
the present cohort of 29 FA-D2 patients with adequate clinical information were of the 
following types and frequencies (Supplementary Table S5): 25/28 (89%) had 
microcephaly, 25/29 (86%) (intrauterine) growth retardation, 21/28 (75%) anomalies 
of skin pigmentation, 21/29 (72%) radial ray defects, 17/28 (61%) microphtalmia, 
10/28 (36%) renal anomalies, 9/28 (32%) malformations of the external ear, 9/29 
(31%) anomalies of the brain (including 5/29 or 17% with hydrocephalus), 7/28 (25%) 
hypogonadism or other genital anomalies, 4/28 (14%) anomalies of the heart and 
4/28 (14%) malformations of the GI tract. Of note was a high proportion of FA-D2 
patients with psychomotor retardation and attention deficit/hyperactivity disorder 
(8/28, 29%). Dysplasia and dislocation of the hip (6/28, 21%) also were relatively 
common. VACTERL-like association (1/28, holoprosencephaly (1/28), the 
Karthagener syndrome (1/28) and the Michelin tire baby syndrome (2/28) were noted 
as distinct disorders occurring in some FA-D2 patients. With the exception of single 
families, there was no general tendency of our families with FA-D2 offspring for 
increased rates of spontaneous abortions. Among the 28 fully informative FA-D2 
patients, there was only a single malignancy (AML) during observation and there was 
no apparent overrepresentation of malignancies in the parents or grandparents of the 
D2 patients in our cohort. 
Median age at diagnosis of these FA-D2 patients was 4 y and 5 mo (n=29). 
Excluding the fetal case (no. 19) and five mosaic patients (no. 3, 14, 15, 25 and 26), 
the median age of transfusion dependency was 10 y 10 mo (n=23). Figure 2 
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compares the progressive hematological course and the outcome of our group of FA-
D2 patients to previously reported altogether 754 North American IFAR patients39. 
BMF in our D2 group (n=23) occurred at an earlier age (median D2 4 y vs. IFAR 6 y 7 
mo, p=0.001; Figure 2A), and the period from BMF to HSCT was shorter (D2 
n(HSCT)=9, median 5 y 6 mo. vs. IFAR n(HSCT)= 218, median 11 y 4 mo; p<0.08; 
Figure 2B). HSCT in our D2 patients was earlier than in the IFAR patients of 
combined groups (median D2 10 y 11 mo vs. IFAR 27 y 11 mo, p<0.01; Figure 2C). 
9/23 FA-D2 patients of our cohort had HSCT. Kaplan-Meier estimates (Figure 2D) 
suggest that our D2 patients (n=23) may have a shorter overall lifespan as their 
survival curve falls below that of the IFAR patients after age 9 y; however, the 
difference of median survival (D2 11 y 4 mo vs. IFAR 24 y 3 mo) was not significant 
due to only two non-mosaic D2 patients who reached adulthood. 
 
FANCD2 and the FANCD2 pseudogenes 
BLAT searches identified two pseudogene regions: FANCD2-P1 spanning 16 kb, 
located about 24 kb upstream of FANCD2, and FANCD2-P2 spanning 31.9 kb, 
located about 1.76 Mb downstream of FANCD2 (Figure 3A). P1 and P2 are in the 
same orientation as the functional gene. They are characterized by high homology 
with certain FANCD2 exons and have retained ordered arrays of their exon 
equivalents. On the other hand, the exon replicas of FANCD2-P1 and FANCD2-P2 
have acquired numerous deletions and insertions. Striking sequence similarity of the 
D2 pseudogenes extends into some FANCD2 introns, prominently the regions of 
IVS21-IVS26. Thus, P1 and P2 reveal recognizable patterns of conserved gene 
structure (Figure 3B). FANCD2-P1 is a rough copy of the front portion of FANCD2 
including, with intermittent gaps, the region of exons 1-18 (homology with FANCD2 
exons 1, 12 to 16 and the 3´ portion of exon 18). The region upstream of FANCD2-P1 
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shares homology with the putative FANCD2 promoter predicted within the CpG-rich 
region of approximately 800 bp upstream of the start codon of the functional gene. 
The corresponding region upstream of P1 is interrupted by an AluY element. 
FANCD2-P2 is an approximate match of the middle portion of FANCD2 spanning, 
also with gaps, the region of exons 12 through 28 (homology with FANCD2 exons 12 
to 14 and 17 to 28). 
 
Mutations in FANCD2 
Unique amplification of the functional FANCD2 gene using primers excluding 
pseudogene sequences resulted in 15 superamplicons (Figure 3C) that were used for 
genomic mutation screens. Studies at the RNA level were implemented to guide the 
genomic analyses. All mutations identified and their predicted consequences at the 
protein level are compiled in Table 1. The distribution of the mutations among the 
individual patients is shown in Supplementary Table S4. 
 
Mutations affecting pre-mRNA splicing 
In PBLs, LCLs and cultured fibroblasts from normal controls, two species of FANCD2 
cDNAs were consistently detected by sequence analysis of the regions 
corresponding to exon 22 (Figure 4A and B) and exons 15-17 (data not shown) due 
to low-level skipping of these exons, consistent with FANCD2 RNA being subject to 
alternative splicing. This finding was confirmed by mRNA stabilization via CHX 
treatments of cultured cells, which resulted in a relative increase of the alternatively 
spliced mRNA species (Figure 4A and C) implying instability of the alternatively 
spliced FANCD2 mRNAs. 
Without CHX treatments, cell lines from patients 2, 8, 9, 10, 14, 15 and 20 in our 
cohort displayed almost equal levels of exon 22 skipping and retention (Figure 4A 
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and D). Patients 3, 4, 5 and 13 showed nearly complete exon 22 skipping, but we 
consistently observed a small amount of correctly spliced mRNA retaining exon 22 
(Figure 4A and E). Genomic sequencing identified a common underlying mutation, 
the base substitution c.1948-16T>G in IVS21. Homozygosity for this mutation was 
observed in patients 3, 4, 5 and 13 with nearly complete skipping of exon 22 and also 
in the deceased patient 25. All of these patients were products of consanguineous 
matings. Patients 9 and 10 with balanced levels of exon 22 skipping and retention 
were compound heterozygous carriers of the mutation. 
A different base substitution preceding exon 22, c.1948-6C>A, was present on 
one allele of the compound-heterozygous patients 2, 8, 14, 15 and 20, likewise 
resulting in similar levels of exon 22 skipping and retention. Both mutations, c.1948-
16C>T and 1948-6C>A, are predicted to disrupt the splice acceptor recognition in 
intron 21 suggested by impaired scores of the 3´splice site relative to wildtype (cf. 
Supplementary Table S6A). 
Three apparently unrelated patients (patients 6, 12 and 30) showed balanced 
levels of skipping and retention of exon 5 due to heterozygous insertional 
mutagenesis by an Alu element between positions c.274-57 and c.274-56 into an AT-
rich target sequence in IVS4. This Alu was identical to the evolutionary young 
subfamily Yb840,41. It was lacking its annotated nucleotides 1-35, had integrated in 
reverse orientation (with its poly-A tail towards the 5´ end of FANCD2) and had 
duplicated the 13-nt sequence c.274-69 to c.274-57 of FANCD2 IVS4 such that this 
duplicated sequence flanked the Alu repeat on either side. Altogether the insertion 
was 298 bp long. Integration site, type, length and orientation of the Alu and the 
duplicated FANCD2 intron sequence were identical in all three patients. 
Aberrant splicing of exons 4, 5, 10, 13, 15-17, 28 and 37 was observed also in 
other patients. Patients 28 and 29 showed skipping of exon 4 due to a base 
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substitution in the preceding canonical splice acceptor site (c.206-2A>T). Patients 26 
and 27 had a base substitution in exon 5 (c.376A>G) abrogating the downstream 
splice donor. This change led to the inclusion of 13 bp of IVS5 into the transcript by 
activating a cryptic 5’-splice site in intron 5 (r.377_378ins13; also previously 
reported24). Patient 18 showed skipping of exon 10 due a base substitution in the 
upstream splice acceptor (c.696-2A>T). Exon 10 skipping was observed in patient 
31, who had a substitution of the last minus one base of exon 10 (c.782A>T). In 
patient 8, we detected a splice acceptor mutation upstream of exon 13 (c.990-1G>A). 
This change results in the activation of a cryptic splice acceptor 8 bp downstream 
and exclusion of the corresponding sequence from the mature mRNA. A 2-bp 
deletion in exon 16 (c.1321_1322delAG) in patient 18 causes skipping of exons 15-
17. In this case, aberrant splicing occurs in the same position as low-grade 
alternative splicing in normal controls, but at heterozygous levels. Patients 10 and 22 
showed inclusion of a 27-bp sequence of intron 28 into mRNA due to a splice donor 
mutation (c.2715+1G>A) and the usage of a cryptic splice donor downstream. Patient 
11 had a base substitution in exon 37 (c.3707G>A, previously reported24) that 
abrogates the normal splice acceptor 25 bp upstream and activates a cryptic site 19 
bp downstream of the mutation, resulting in skipping of 44 bp. Interestingly, an 
adjacent base substitution (c.3706C>A) in patient 32 generates a new splice 
acceptor that is used instead of the normal one 23 bp upstream, leading to skipping 
of the 24 nt in between. All of these splicing aberrations were due to heterozygous 
mutations whereas patient 1 showed homozygous exonization of an IVS9 fragment 
due to a mutation in intron 9 (c.696-121C>G), which activates cryptic splice sites. 
Predicted scores and consequences of some of these splice mutations are computed 
in Supplementary Tables S6. Apart from 1321_1322delAG causing skipping of exons 
15-17, all mutations affecting splicing in the patients of this study result in frameshifts 
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and subsequent premature termination of translation. More than half, i.e., 30/58 
mutation alleles of the 29 fully informative FA-D2 patients, or 34/66 of all, were 
splicing mutations. Thus, the most prevalent effect of FANCD2 mutations involves 
abnormal splicing patterns. 
 
Other mutations 
There were five different heterozygous nonsense mutations in nine patients from six 
families (c.757C>T, siblings 23 and 24; c.1092G>A, patient 7; c.2404C>T, patient 21; 
c.2775_2776CC>TT, siblings 14 and 15; c.3803G>A, patient 6, siblings 26 and 27; 
Table 1 and Supplementary Table S4). In addition, we detected five different 
missense mutations in eleven patients from nine families (c.692T>G, patient 19; 
c.904C>T, patient 7, identical to a previously reported mutation24; c.1367T>G, 
siblings 23 and 24; c.1370T>C, patient 31; c.2444G>A, siblings 16 and 17, patients 
19, 21, 22 and 30). These amino acid substitutions were classified as missense 
mutations because of their absence from normal controls, their absence from FA-D2 
patients of our cohort with other biallelic mutations and their occurrence at 
evolutionary conserved residues. Missense mutations were either compound 
heterozygous in combination with other types of FANCD2 mutations or homozygous 
in consanguineous families. Three unrelated patients had small deletions 
(c.2660delA, patient 20; c.3453_3456delCAAA, patient 12; c.3599delT, patient 2) 
resulting in frameshifts. Another small deletion was in frame and affected a single 
codon (c.810_812delGTC, patient 9). There was only a single small frameshift 
duplication (c.2835dupC, patient 11). A large genomic deletion 
(g.22875_23333del459) spanning the entire exon 17 (similar to a mutation previously 
reported without defined breakpoints24) adjacent 71 bp of intron 16 and 256 bp of 
intron 17 was found in sibling pair 28 and 29. This deletion resulted in a net loss of 41 
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aa. A large genomic duplication in patient 33 included exons 11-14 and resulted in 
the insertion of 132 aa. Both gross gene rearrangements retained the reading frame. 
In all of our patients, nonsense mutations, deletions and insertions were exclusively 
affecting single alleles in combination with splice or missense mutations. 
A unique case was a compound heterozygous start codon mutation (c.2T>C) in 
patient 32. 
 Figure 5 illustrates the distribution of FANCD2 mutations that were identified in 
this study, including those of three FA-D2 patients previously reported24. 
 
Ethnic associations and shared alleles 
Relatively severe birth defects and early hematological onset were observed in three 
patients (4, 5 and 13) homozygous for the splice mutation c.1948-16T>G with exon 
22 skipping. These three patients and two other homozygotes with reverse 
mosaicism in the hematopoietic system (patients 3 and 25) were all from four 
consanguineous Turkish families. Of two FA-D2 patients compound heterozygous for 
this mutation, one was also of Turkish origin; the other came from eastern Czech 
Republic. The splice mutation c.1948-6C>A, likewise leading to exon 22 skipping, 
was detected in five patients (patients 2, 8, 14, 15 and 20), including two sisters 
(patients 14 and 15). These patients came from three families in Northern Germany 
and a German immigrant family in the US (patient 20). They presented with 
intermediate phenotypic and hematological severity. Relatively mild birth defects and 
a protracted hematological course into adulthood was observed in two siblings from a 
consanguineous Spanish family (patients 16 and 17) with the homozygous missense 
substitution c.2444G>A. Of four compound heterozygotes for this mutation with mild 
disease manifestations, one had mixed ethnicity (patient 19), one was Hispanic 
American (patient 21), one had Sicilian (patient 22) and another Spanish and 
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Portuguese ancestry (patient 30). The insertion of an AluYb8 element was found 
compound-heterozygous in a patient each of German (patient 6), Danish (patient 12), 
and Spanish/Portuguese FA-D2 (patient 30) descent. We therefore considered the 
latter mutation as recurrent rather than ethnically associated. All other mutations did 
not occur in more than two families. 
On haplotype analysis, all patients homozygous for the mutation detected in the 
Turkish population (c.1948-16T>G; patients 3, 4, 5, 13 and 25) were homozygous for 
markers D3S1597, D3S1938, D3S3611 and D3S1675. The resulting haplotype was 
shared, in heterozygous state, with the non-consanguineous compound 
heterozygous Turkish patient (no. 10). The Czech patient (no. 9) with this mutation 
had a different haplotype. Lack of homozygotes for the intron 21 mutation prevalent 
in the German population (c.1948-6C>A; patients 2, 8, 14, 15 and 20) and 
unavailability of patients’ parents precluded construction of a mutation-associated 
haplotype. However, all patients with this mutation had one or two identical marker(s) 
at least on one side of their mutated FANCD2 gene. This finding suggests that 
c.1948-6C>A is an old mutation with erosion of an ancient haplotype. The 
consanguineous siblings (patients 16 and 17) homozygous for the mutation prevalent 
in Spanish or Southern European populations (c.2444G>A) were also homozygous 
for the set of markers used. Of their common haplotype, the microsatellite markers 
adjacent to FANCD2 were shared with a Hispanic patient (no. 21), a patient with 
Sicilian ancestry (no. 22) and a patient of Spanish/Portuguese descent (no. 30), all 
compound heterozygotes for this mutation. Additional support for a conserved 
haplotype came from linkage disequilibrium. All of the patients homo- or 
heterozygous for the mutation c.2444G>A were also homo- or heterozygous for the 
polymorphism c.2702G>T (p.G901V). Sequence analysis of the parents indicated 
that both substitutions were on the same allele. A single patient (no. 19) with the 
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mutation c.2444G>A neither shared the haplotype nor the polymorphism c.2702G>T. 
Apart from c.2702G>T that was also observed without association with the mutation 
c.2444G>A, the only new FANCD2 polymorphisms detected in our study were 
c.3978C>T and c.4478A>G in the 3’-UTR, all others have been previously reported24. 
Despite clear ethnical association of the patients with the insertion of an AluYb8 
element in intron 4, it nevertheless seems unlikely that an identical event would have 
occurred three times independently. Two of these patients (6 and 12) shared all of 
the four markers studied. Patient 30 with the same mutation had retained a single 
identical marker adjacent to FANCD2. A base substitution in the Alu sequence, 
260G>A, present in all three cases but in less than 10% of complete AluYb8 
elements in the human genome (BLAT) further suggests that the Alu insertion goes 
back to a single event and is an ancient rather than a recurrent mutation. 
 
Reverse mosaicism 
Among the 28 fully informative FA-D2 patients in this study (excluding the fetal case 
no. 19), five (no. 3, 14, 15, 25 and 26) developed reverse mosaicism in the 
hematopoietic system. Mosaic patients were recognized by the facts that they had 
levels of both FANCD2-S and -L in protein from LCLs, comparable to normal controls 
(Figure 6A), that they had low chromosome breakage rates in blood and blood-
derived LCLs (Supplementary Table S4) and that they had lost the typical G2 phase 
arrest of their lymphocytes after exposure to MMC (Figure 6B). Nonetheless, these 
patients had the characteristic clinical FA phenotype and their cultured fibroblasts 
had preserved MMC sensitivity, indicated by elevated chromosome breakage and G2 
phase arrest (Figure 6B). Molecular studies confirmed these findings. Two patients 
with heterozygous base substitutions in the coding sequence, resulting in a nonsense 
(patient 14) and a splice mutation (patient 26), showed reversion to the respective 
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wildtype bases in primary blood cells and LCLs. The mechanism of these reversions 
is not clear and could involve back mutation, recombination with LOH or 
recombination with gene conversion. Intragenic mitotic crossover is the likely but not 
proven mechanism of mosaicism in the sibling of patient 14 (no. 15) who had 
retained her dinucleotide substitution in her peripheral blood cells. Two patients (3 
and 25) with the c.1948-16T>G splice mutation had different second site 
compensatory mutations nearby. Clinically, 3/5 mosaic patients (3, 14 and 15) in the 
present cohort experienced a mild or protracted hematological course. The other 2/5 
patients (25 and 26) had no apparent benefit from their mosaicism; one of them 
required relatively early HSCT and the other died of intracranial hemorrhage 
(Supplementary Table S5). The rate of 17% mosaic FA-D2 patients in our study is 
within the 15%42 to 20%43 or 25%44 range reported for other complementation 
groups. With a rate comparable to FANCA, FANCD2 appears to be another FA gene 
particularly prone to reverse mosaicism. 
 
Residual FANCD2 protein 
A surprising finding was the presence of residual FANCD2 protein in PBLs and LCLs 
of every FA-D2 patient tested. Detection of residual protein required overexposure of 
FANCD2 immunoblots (Figure 7A). Unlike standard exposure that showed no 
FANCD2 bands in most of the FA-D2 cell lines (cf. Figure 1), both FANCD2-S and 
FANCD2-L bands were detected when films were exposed overnight. As the study 
progressed, it became evident that the cell lines initially detected with residual protein 
were those with the highest levels. When we systematically re-examined all of our 
FA-D2 lines, all 21 LCLs available from our 29 fully informative FA-D2 patients had 
minute but unequivocal amounts of residual protein (Supplementary Table S4). This 
was also true for CD3/CD28/IL-2 stimulated PBL cultures from patient 13. Primary 
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fibroblasts normally have lower levels of FANCD2 relative to total protein than LCLs, 
and this might be the reason why detection of residual FANCD2 remained ambiguous 
in a prenatal case (patient 19) with only fibroblasts available. Because of lack of 
LCLs, two affected siblings (patients 4 and 17) could not be tested. Finally, five of our 
patients were mosaic leaving 8/29 patients unconfirmed for residual protein. Given 
the normal amounts of FANCD2 protein in the mosaic patients and the fact that the 
non-mosaic patients had high chromosome breakage rates and G2 phase arrest, we 
consider it unlikely that undetected mosaicism accounts for the presence of residual 
protein in the remainder of our patients. Densitometry suggested reductions of 
residual FANCD2 protein in the order of 1/100 to 1/1000 relative to wildtype, with the 
expression differing greatly amongst individual LCLs (Figure 7A). FA-D2 LCLs with 
the highest levels of residual FANCD2 were used to examine its characteristics on 
overexposed blots. The intensity of the FANCD2-L band increased as a function of 
the concentration of the DNA crosslinking agent (Figure 7B) and the period of 
treatment (not shown). This time and concentration dependency suggests genuine 
biochemical activity of the residual FANCD2 protein, implying that most, if not all, 
cases of FA-D2 result from functionally hypomorphic mutations. 
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Discussion 
Our results suggest that FA-D2 is a more frequent FA complementation group than 
previously reported2,22,23. The relatively large proportion of Turkish FA-D2 patients in 
the present study–about 10% of the patients studied in Germany–appears to be due 
to a founder effect for the FANCD2 mutation c.1948-16T>G among individuals of 
Turkish origin. This is similar to the disparity in the frequency of FA-C patients in the 
IFAR database compared to the European FA population. The proportion of FA-C 
patients in the IFAR is 15%45, compared to only 10% in the European dataset2. This 
is due to the relatively high frequency of Ashkenazi Jewish FA patients in the IFAR 
with the prevalent FANCC mutation c.456+4A>G (formerly IVS4+4A>G)30, 
comprising 7.5% of all IFAR patients and 50% of the FA-C patients therein. We 
calculate roughly that about 6% of FA patients belong to complementation group D2, 
which is supported by independent studies with a figure of 4/53 ≈ 7.5%42, 3/73 ≈ 
4.1%46 and an estimate of 5%45, as recently reported. 
The D2 patients in our cohort displayed anomalies and malformations typical of 
FA such that there were no exceptional clinical features that had not previously been 
observed47. However, it is remarkable that not a single D2 patient lacked 
phenotypical manifestations, whereas the proportion of FA patients without 
anomalies and malformations is generally estimated as high as 30%22. Growth 
retardation was present in 86% of the present cohort, substantially higher than the 
58%48 and 63%22 reported. Microcephaly was present in 89% of the FA-D2 cases; in 
contrast, Faivre et al.48 found anomalies of the head in only 56%. Anomalies of skin 
pigmentation were present in 75% of our FA-D2 cohort compared to 71% and 
64%22,48. 72% of our FA-D2 patients had radial ray defects in contrast to only 47%48 
or 49.1% 47 of all FA patients. 61% of the patients in the present study had 
microphtalmia, whereas 38% have been reported in other FA patients22. As with 
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these rather common phenotypic alterations, FA-D2 patients showed also higher 
rates of rare FA features such as psychomotor retardation and hyperactivity attention 
deficit disorder. Psychomotor retardation was present in 29% of our FA-D2 cohort 
versus 12% or 10% mentally retarded individuals in other studies22,48. As many as 
31% of our FA-D2 patients had anomalies of the brain, whereas other studies report 
such alterations in the order of 4.5%48, 7.7%47 and 8%22 of their FA patients. 17% of 
our D2 patients with brain anomalies had hydrocephalus, in contrast to 4.6% 
reported47. Since several labs contributed to the present study, and since all of our 
D2 patients came from previously unassigned FA patients, it is unlikely that our rates 
reflect major biases. A more severe D2 phenotype has also been observed in 
drosophila comparing Fancd2 and Fancl knock-down21. Given the high frequency of 
phenotypic alterations, it is not surprising that in 30% of our FA-D2 patients the 
diagnosis of FA was made by the age of 2 y, and the median of age at diagnosis was 
4.5 y which is considerably younger than in other FA patients where only in 30% the 
diagnosis is made before onset of hematological manifestations at the median age of 
7.6 y49. In addition to an earlier median age of hematological onset (BMF) in our FA 
patients, there was a shorter median period between BMF and HSCT, earlier HSCT 
and a tendency towards shorter median survival than all FA in the IFAR39. However, 
due to relatively small numbers and the relative deficit of older patients in our cohort, 
statistical significance was not reached for all of these end points. HSCT appears to 
be a therapeutic option also in group FA-D2 as nine transplanted non-mosaic 
patients and one mosaic patient of our cohort suggest, although deficient ATM/ATR-
dependent phosphorylation of FANCD250,51,52 could theoretically involve additional 
toxicity of conditioning. Again, our data suggests that FA-D2 patients represent a 
group with frequent but typical congenital anomalies and malformations, and with 
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relatively early hematological manifestations, compared to most other FA 
complementation groups. 
Among the FA proteins, FANCD2 is unique since the presence of residual protein 
and the demonstration of its activation can be accomplished in a single assay. In our 
cohort, LCLs and PBLs from 21 fully informative, non-mosaic FA-D2 patients studied 
showed traces of residual FANCD2 protein. Importantly, the residual protein always 
consisted of both FANCD2 isoforms, and the typical time- and dose-dependent 
induction of FANCD2-L was maintained, suggesting a preserved function. 
Differences in expression levels of residual FANCD2 between individual LCLs might 
result from variations of conserved splice site recognition, in mRNA and protein 
stability, and, very clearly, from differences in cell growth. FANCD2 is highly 
expressed and monoubiquitinated in the S-phase of the cell cycle 8,53. The proportion 
of S-phase cells is a function of cell growth such that differences in cell proliferation 
between individual cell lines account for the wide variation of FANCD2 protein levels 
and render any quantitative mutation-specific comparisons of residual FANCD2 
protein levels close to impossible. The existence of residual protein has previously 
been described for other FA-D2 patients7,24,42 but our study confirms residual protein 
as a consistent and in all likelihood essential feature of FA-D2 patient cells. Somatic 
reversion as a cause of residual protein levels could be excluded because the 
diagnosis of FA in these of our D2 patients was based on hypersensitivity towards 
crosslinking agents. 
FANCD2 is targeted to chromatin following DNA damage-dependent 
monoubiquitination where it interacts with the highly conserved C-terminal region of 
BRCA254. FANCD2-L promotes BRCA2 loading onto a chromatin complex that is 
required for effective, but RAD51-independent DNA repair13,55. The examination of 
DT40 cell lines revealed that components of the FA core complex have additional 
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functions in DNA repair pathways which seem to be independent of 
monoubiquitination and chromatin targeting of Fancd256. However, the common 
pathway of FANCD2 and FANCD1/BRCA2 appears to be crucial for functional 
resolution of ICL-induced stalled replication forks and, in order for humans to be 
viable, may require residual protein activity. 
Despite a rather severe phenotype in most of the FA-D2 patients, the vast 
majority of our FA-D2 patients were found to carry leaky mutations, merely affecting 
splicing, and displayed residual FANCD2 protein of both isotypes in their cell lines. 
Splicing mutations have become an increasingly successful target for experimental 
therapeutic approaches. Modified and antisense oligonucleotides have been used to 
inhibit cryptic exons or to activate regular exons weakened by mutations via targeting 
of the oligonucleotides to the desired transcript. This approach could eventually lead 
to effective therapies for the correction of erroneous splicing (reviewed in56,57). The 
tight regulation of FANCD2 expression and activation, and the presence of low-
abundant wildtype gene products associated with FANCD2 mutations should render 
FANCD2 an ideal candidate for RNA-reprogramming strategies such as 
spliceosome-mediated RNA trans-splicing (SMaRT; reviewed in57,58). 
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Web resources 
Genomic FANCD2 sequences were compared by BLAT homology searches 
(http://genome.ucsc.edu/cgi-bin/hgBlat) and the Ensembl genome browser 
(http://www.ensembl.org/). Polypeptide sequences were compared using the 
Windows interface Clustal X (ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX), version 1.81, 
for the Clustal W multiple sequence alignment program. Promoter analyses were 
done using the CpG island explorer59 (http://bioinfo.hku.hk/cpgieintro.html), version 
1.9, at the settings GC 60%, CpG O/E ratio 0.7 and minimum length 500 nt. Analysis 
of repetitive elements was done using the Repeatmasker software 
(http://www.repeatmasker.org). Predicted splice donor performance was calculated 
using the Splicefinder algorithm (http://www.splicefinder.org). Deduced splice 
acceptor function was estimated using a maximum entropy model 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html). Regulatory 
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splice sequences were analyzed using the ESE finder (http://rulai.cshl.edu/tools/ESE) 
and the Rescue-ESE (http://genes.mit.edu/burgelab/rescue-ese). 
The NCBI (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) nucleotide sequences NM 
033084 (43 exons) and AF 340183 (44 exons) were used as the human FANCD2 
cDNA reference. The genomic reference sequence was ENSG00000144554. Fancd2 
sequence information of other species is available at the same website. Fancd2 
protein sequences of different species including Homo sapiens were from the Swiss-
Prot database (http://www.expasy.org/sprot/).  
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Table 1. Identified FANCD2 mutations and their effects 
 
Mutation* Consequence* Location 
Exon/Intron gDNA RNA Protein 
Patient
No. 
Exon 2 c.2T>C r.2T>C Failure of normal 
translation initiation 
32 
Intron 3 c.206−2A>T 
(IVS3−2A>T) 
r.206_273del68 
(exon 4 skipping) 
p.A69DfsX7 28, 29 
Intron 4 c.274−57_−56insinvAluYb8
nt36_319 
+dup c.274−69_−57 
r.274_377del104 
(exon 5 skipping) 
p.I92YfsX7 6, 12, 30 
Exon 5 c.376A>G r.376A>G+r.377_378ins13 
(aberrant splicing) 
p.S126RfsX12 26, 27 
Exon 9 c.692T>G r.692T>G p.L231R 19 
Intron 9 c.696−121C>G 
(IVS9−121C>G) 
r.695+1619_696-126ins34 
(exonization) 
p.S232insQNNFX 1 
 c.696−2A>T 
(IVS9−2A>T) 
r.696_783del88 
(exon 10 skipping) 
p.S232RfsX6 18 
Exon 10 c.757C>T r.757C>T p.R253X 23, 24 
 c.782A>T r.696_783del88 
(exon 10 skipping) 
p.S232RfsX6 31, 33 
Exon 11 c.810_812delGTC r.810_812delGTC p.S271del 9 
Exon 12 c.904C>T r.904C>T p.R302W 7 
Intron 12 c.990−1G>A 
(IVS12−1G>A) 
r.990del8 
(aberrant splicing) 
p.S330RfsX16 8 
Exon 13 c.1092G>A r.1092G>A p.W364X 7 
Intron 14 g.13377_17458dup4082 
(Duplication including exons 
11_14)  
r.784_1134dup 
(duplication of 351 nt in frame) 
p.262_378dup 
(duplication of 117 aa) 
33 
Exon 16 c.1321_1322delAG r.1135_1545del411 
(exon 15-17 skipping) 
p.V379_K515del 18 
 c.1367T>G r.1367T>G p.L456R 23, 24 
 c.1370T>C r.1370T>C p.L457P 31 
Exon 17 g.22875_23333del459 
(c.1414−71_c.1545+256del459) 
r.1414_1545del132 p.E472_K515del 28, 29 
Intron 21 c.1948−16T>G 
(IVS21−16T>G) 
r.1948_2021del74 
(exon 22 skipping) 
p.E650X 3, 4, 5, 
9, 10, 
13, 25 
 c.1948−6C>A 
(IVS21−6C>A) 
r.1948_2021del74 
(exon 22 skipping) 
p.E650X 2, 8, 14, 
15, 20 
Exon 26 c.2404C>T r.2404C>T p.Q802X 21 
 c.2444G>A r.2444G>A p.R815Q 16, 17, 
19, 21, 
22, 30 
Exon 28 c.2660delA r.2660delA p.E888RfsX16 20 
Intron 28 c.2715+1G>A 
(IVS28+1G>A) 
r.2715_2716ins27 
(aberrant splicing) 
p.E906LfsX4 10, 22 
Exon 29 c. 2775_2776CC>TT r. 2775_2776CC>TT p.R926X 14, 15 
 c.2835dupC r.2835dupC p.D947RfsX3 11 
Exon 34 c.3453_3456delCAAA r.3453_3456delCAAA p.N1151KfsX46 12 
Exon 36 c.3599delT r.3599delT p.I1200KfsX12 2 
Exon 37 c.3706C>A r.3684_3707del24 
(aberrant splicing) 
p.R1228S_F1235del 32 
 c.3707G>A r.3684_3727del44 
(aberrant splicing) 
p.H1229EfsX7 11 
Exon 38 c.3803G>A r.3803G>A p.W1268X 6, 26, 27 
* Nomenclature according to the Human Genome Variation Society (http://hgvs.org/mutnomen/recs) 
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Figure Legends 
 
Figure 1. Delineation of FA-D2. (A) Schematic representation of the retroviral vector 
construct S11FD2IN expressing FANCD2 cDNA. Used for cloning were the 5’ EcoR I 
and the 3’ Sal I (insert) and BamH I (vector) sites; the two latter were destroyed by 
blunting. The target vector S11IN without FANCD2 is shown underneath. 
Abbreviations: L, long terminal repeat; I, internal ribosomal entry site; N, neomycin 
resistance gene. (B) Assignment to group FA-D2 based on the absence of either 
FANCD2 band on immunoblots after exposure of the patients’ cells to MMC, here 
shown for a LCL from patient 6 (lane 2). Transduction with FANCD2 cDNA using 
S11FD2IN restores both isoforms of FANCD2, S and L (lane 3), similar to a non-
transduced normal control (lane 1). Transduction with FANCA cDNA in the same 
vector fails to show such restoration (lane 4). (C) Assignment to group FA-D2 based 
on cell cycle analysis: After exposure to MMC, the LCL of the same patient shows 
pronounced G2 phase arrest (56.6%, lane 2, Hoechst 33342 staining). Transduction 
with FANCD2 cDNA using S11FD2IN reduces the G2 phase to normal (14.9%, lane 
3, arrow), similar to the non-transduced normal control (16.6%, lane 1). Transduction 
with FANCA cDNA in the same vector fails to reverse the G2 phase arrest (53.1%, 
lane 4). (D) and (E) are analogous to (B) and (C) and show complemention with 
cultured fibroblasts from patient 10; staining in (E) was with DAPI. G2 phase 
proportions in (E) are 20.3% (lane 1, control), 61.3% (lane 2, non-transduced FA), 
19.9% (lane 3, FANCD2-transduced FA) and 58.5% (lane 4, FANCA-transduced FA). 
 
Figure 2. Clinical course of 23 fully informative, non-mosaic FA-D2 patients in 
this study. (A) The cumulative incidence of bone marrow failure (BMF) of the FA-D2 
patients in the present study (FA-D2) precedes that of all FA patients in the IFAR 
(IFAR)39 (p=0.001). (B) The period from BMF to hematological stem cell 
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transplantation (HSCT) was shorter in the patients of the present study than in those 
of the IFAR39 (trending, p<0.08. (C) Cumulative incidence of HSCT of the FA-D2 
patients in our study likewise antedates that of all FA patients in the IFAR39 (p<0.01). 
(D) Kaplan-Meier curves of survival suggest higher death rates of the FA-D2 patients 
than of all FA patients in the IFAR after 10 years of age 
 
Figure 3. Topography of FANCD2, its pseudogenes and the superamplicons. 
(A) The two pseudogenes, FANCD2-P1 and FANCD2-P2, are located upstream and 
downstream of the functional FANCD2 gene, respectively. All three have the same 
orientation. The scale denotes Mbp on chromosome 11. (B) FANCD2 exons and their 
pseudogene equivalents and are connected by dashed lines containing percentages 
of nucleotide identity. Homology also extends into many introns nearby as indicated 
by the boxes beyond and below the active gene. (C) Graphical presentation of the 
positions and sizes of 15 superamplicons relative to the active gene in B. These 
amplicons represent FANCD2 exon-exon or exon-intron regions. Unique primer 
binding sites ensure specific amplification. 
 
Figure 4. Exon 22 splicing. (A) Schematical depiction of the splicing patterns 
resulting from exon 22 retention or skipping. (B) cDNA sequencing in normal controls 
shows abundance of exon 22 sequence following that of exon 21 but also low level 
underlying sequence readable as exon 23. (C) Treatments of normal control cells 
with CHX for 4 h prior to cDNA synthesis increase the relative level of sequence with 
exon 22 skipping. (D) Heterozygotes for splice acceptor mutations in intron 21 show 
comparable levels of inclusion and exclusion of exon 22 sequence following that of 
exon 21. (E) Homozygotes for splice acceptor mutations in intron 21 reveal 
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abundance of exon 23 sequence following that of exon 21 but also low level 
underlying sequence readable as exon 22. 
 
Figure 5. Positions and identity of mutations detected in FANCD2. Mutations 
identified in the present study are shown above, previously reported mutations24 
underneath the schematical display of FANCD2 cDNA. Solid squares (■) represent 
mutations resulting in aberrant splicing patterns, solid circles (●) nonsense mutations, 
open circles (○) missense mutations, solid triangles (▲) frameshift deletions or 
duplications and open triangles (∆) in frame deletions or duplications. 1 denotes 
homozygous occurrence (2 alleles), 2 affected sibling (relationship bias). 
 
Figure 6. Reverse mosaicism. (A) Blood-derived cells from FA-D2 patients with 
reverse mosaicism of the hematopoietic system (patients 3 and 26, LCLs; patient 14, 
stimulated PBL; lanes 2, 3 and 4) reveal both FANCD2 bands at levels similar to a 
random normal control (lane 1) after exposure to MMC. RAD50 was used as loading 
control. (B) In addition, these LCLs and PBL fail to show G2 phase arrest on flow 
cytometric cell cycle distributions in response to MMC (black histograms, DAPI stain; 
CON, 8.0% G2;  patient 3, 8.8% G2; patient 14, 8.8% G2; patient 26, 10.4% G2), 
whereas corresponding cultured FA-D2 fibroblasts retain high G2 phase 
accumulations, which is in contrast to the non-FA control (superimposed grey 
histograms; CON, 22.6% G2; patient 3, 53.2% G2; patient 14, 56.0% G2; patient 26, 
54.8% G2). 
 
Figure 7. Residual FANCD2 protein. (A) Blood-derived cells from non-mosaic FA-
D2 patients (examplified 13, 5, 1, 21, 2, 6, 11 and 28) show faint, but conspicuous 
FANCD2 bands of both species in response to MMC exclusively on overexposed 
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immunoblots as indicated by the very intense FANCD2 signals of the normal controls 
(patient 13, stimulated PBL; patients 5, 1, 21, 2, 6, 11 and 28, LCLs; loading control 
RAD50). The individual abundance of residual protein varies considerably at low 
levels. (B) LCLs were subjected to the indicated concentrations of hydroxyurea (HU) 
for 16 h. On an overexposed blot, the FANCD2-L band of the residual protein in the 
LCL from patient 21 increases with the HU concentration in a dose-dependent 
response. This reaction is similar to that of a normal control LCL distinctive by its 
prominent FANCD2 signals. 
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Supplementary Table S1A. FANCD2 cDNA amplification primers 
 
PCR 
Fragment 
Designation Binding 
Position 
Sequence (5´→3´) Designation Binding 
position 
Sequence (5´→3´) PCR Product 
Size (bp) 
1 FA-D2, Fr.1 F -47 to -27 GCGACGGCTTCTCGGAAGTAA FA-D2, Fr.1 R 998 to 976 CTGTAACCGTGATGGCAAAACAC 998 
2 FA-D2, Fr.2 F 763 to 787 GACCCAAACTTCCTATTGAAGGTTC FA-D2, Fr.2 R 1996 to 1975 CTACGAAGGCATCCTGGAAATC 1234 
3 FA-D2, Fr.3 F 1757 to 1777 CGGCAGACAGAAGTGAATCAC FA-D2, Fr.3 R 2979 to 2958 GTTCTTGAGAAAGGGGACTCTC 1223 
4 FA-D2, Fr.4 F 2804 to 2829 TTCTACATTGTGGACTTGTGACGAAG FA-D2, Fr.4 R 3942 to 3922 GTCTAGGAGCGGCATACATTG 1139 
5 FA-D2, Fr.5(L) F 3761 to 3781 CAGCAGACTCGCAGCAGATTC FA-D2, Fr.5(L) R 4700 to 4679 GACTCTGTGCTTTGGCTTTCAC 940 
 
 
Supplementary Table S1B. FANCD2 cDNA sequencing primers 
 
Designation Binding 
Position 
Sequence (5´→3´) Designation Binding 
position 
Sequence (5´→3´) 
sFA-D2, 244 F 244 to 263 ACCCTGAGGAGACACCCTTC sFA-D2, 367 R 367 to 347 CATCCTGCAGACGCTCACAAG 
sFA-D2, 545 F 545 to 566 GGCTTGACAGAGTTGTGGATGG sFA-D2, 621 R 621 to 600 CAGGTTCTCTGGAGCAATACTG 
sFA-D2, 1011 F 1011 to 1033 CAGCGGTCAGAGCTGTATTATTC sFA-D2, 951 R 951 to 929 CTGTAACCGTGATGGCAAAACAC 
sFA-D2, 1308 F 1308 to 1327 GTCGCTGGCTCAGAGTTTGC sFA-D2, 1158 R 1183 to 1158 TCTGAGTATTGGTGCTATAGATGATG 
sFA-D2, 1574 F 1574 to 1596 CCCCTCAGCAAATACGAAAACTC sFA-D2, 1414 R 1414 to 1396 CCTGCTGGCAGTACGTGTC 
sFA-D2, 2142 F 2142 to 2162 GGTGACCTCACAGGAATCAGG sFA-D2, 1704 R 1704 to 1684 GAATACGGTGCTAGAGAGCTG 
sFA-D2, 2381 F 2381 to 2404 GAGAGATTGTAAATGCCTTCTGCC sFA-D2, 2253 R 2253 to 2232 CTCCTCCAAGTTTCCGTTATGC 
sFA-D2, 2679 F 2679 to 2699 TGACCCTACGCCATCTCATAG sFA-D2, 2526 R 2526 to 2505 GTTTCCAAGAGGAGGGACATAG 
sFA-D2, 3268 F 3268 to 3288 GCCCTCCATGTCCTTAGTAGC sFA-D2, 3346 R 3346 to 3328 GGACGCTCTGGCTGAGTAG 
sFA-D2, 3573 F 3573 to 3594 GCACACAGAGAGCATTCTGAAG sFA-D2, 3674 R 3674 to 3653 GTAGGGAATGTGGAGGAAGATG 
sFA-D2, 4049 F 4049 to 4069 ACACGAGACTCACCCAACATG sFA-D2, 4159 R 4159 to 4139 CCAGCCAGAAAGCCTCTCTAC 
sFA-D2, 4303 F 4303 to 4323 GAGTCTGGCACTGATGGTTGC sFA-D2, 4409 R 4409 to 4387 GGGAATGGAAATGGGCATAGAAG 
 
 
 
Supplementary Table S2A. FANCD2 superamplicon primers 
 
Super-
amplicon 
Containing 
Exons 
Designation Sequence (5´→3´) Designation Sequence (5´→3´) PCR Product 
Size (bp) 
I 1, 2 hFANCD2_exon1_F TATGCCCGGCTAGCACAGAA hFANCD2_super_1_2_R GGCCCACAGTTTCCGTTTCT 4346 
II 3 hFANCD2_super_3_3_F  GTGTCACGTGTCTGTAATCTC  hFANCD2_super_3_3_R  CTGGGACTACAGACACGTTTT 2323 
III 7,8,9 hFANCD2_super_7_14_F  TGGGTTTGGTAGGGTAATGTC  hFANCD2_exon9_R  TACTCATGAAGGGGGGTATCA  4595 
IV 10,11,12,13,14 hFANCD2_exon10_F GCCCAGCTCTGTTCAAACCA  hFANCD2_super_7_14_R  TTAAGACCCAGCGAGGTATTC  5635 
V 13,14,15,16,17 FA-D2, sup13-I17 F CATGGCAGGAACTCCGATCTTG FA-D2, sup13-I17 F CTCCCTTAAAAGCTCAAAGCTCAAGTTC 8858 
VI 19, 20 hFANCD2_super_19_22_F  ACGTAATCACCCCTGTAATCC  hFANCD2_exon20_R TGACAGAGCGAGACTCTCTAA  2749 
VII 21,22,23 FA-D2, 21_23, F GCTTCTAGTCACTGTCAGTTCACCAG FA-D2, 21_23, R  ACGTTGGCCAGAAAGTAATCTCAG 2518 
VIII 23,24,25,26 hFANCD2_super_23_29_F  GGCCTTGTGCTAAGTGCTTTT   hFANCD2_exon26_R  TCAGGGATATTGGCCTGAGAT  3252 
IX 27,28,29 hFANCD2_exon27_F  GCATTCAGCCATGCTTGGTAA  hFANCD2_super_23_29_R  CACTGCAAACTGCTCACTCAA  3371 
X 30 hFANCD2_super_30_32_F  CCAAAGTACTGGGAGTTTGAG  hFANCD2_exon30_R  TACCCAGTGACCCAAACACAA  2186 
XI 31,32 hFANCD2_exon31_F CCATTGCGAACCCTTAGTTTC  hFANCD2_super_30_32_R  ACCCTGGTGGACATACCTTTT  299 
XII 33,34 hFANCD2_super_33_36_F  GAGCAATTTAGCCTGTGGTTTT  hFANCD2_exon34_R  TATAGCAAGAGGGCCTATCCA  3457 
XIII 35,36 hFANCD2_exon35_F  TTAGACCGGGAACGTCTTAGT  hFANCD2_super_33_36_R  TCTGGGCAACAGAACAAGCAA  2040 
XIV 43a hFANCD2_super_43_44_F  AGGGTCCTGAGACTATATACC  hFANCD2_exon43a_R  AGCATGATCTCGGCTCACCA  2040 
XV 44 hFANCD2_exon44_F  CACCCAGAGCAGTAACCTAAA  hFANCD2_super_43_44_R  ACCATCTGGCCGACATGGTA  464 
 
 
Supplementary Table S2B. FANCD2 exon primers 
 
Exon Designation Sequence (5´→3´) Designation Sequence (5´→3´) PCR Product 
Size (bp) 
1 hFANCD2_exon1_F TATGCCCGGCTAGCACAGAA hFANCD2_exon1_R TCCCATCTCAGGGCAGATGA 324 
2 hFANCD2_exon2_F  CCCCTCTGATTTTGGATAGAG hFANCD2_exon2_R  TCTCTCACATGCCTCACACAT 258 
3 hFANCD2_exon3_F  GACACATCAGTTTTCCTCTCAT hFANCD2_exon3_R  AAGATGGATGGCCCTCTGATT  354 
4 hFANCD2_exon4_F TGGTTTCATCAGGCAAGAAACT hFANCD2_exon4_R  AATCATTCTAGCCCACTCAACT 253 
4/5 FA-D2, exon 4 II F GAGAAGGAAAACTATGGTAGGAAAC FA-D2, exon 5 II R GTGTAAGCTCTGTTTTCCTCAGAG 509 
5 hFANCD2_exon5_F  GCTTGTGCCAGCATAACTCTA  hFANCD2_exon5_R  AGCCCCATGAAGTTGGCAAAA 298 
6 hFANCD2_exon6_F  GAGCCATCTGCTCATTTCTGT  hFANCD2_exon6_R  GCTGTGCTAAAGCTGCTACAA  341 
7 hFANCD2_exon7_F  AATCTCGGCTCACTGCAATCT  hFANCD2_exon7_R  CAGAGAAACCAATAGTTTTCAG  280 
8 hFANCD2_exon8_F  TAGTGCAGTGCCGAATGCATA  hFANCD2_exon8_R  AGCTAATGGATGGATGGAAAAG  333 
9 hFANCD2_exon9_F  TTCACACGTAGGTAGTCTTTCT  hFANCD2_exon9_R  TACTCATGAAGGGGGGTATCA  323 
10 hFANCD2_exon10_F GCCCAGCTCTGTTCAAACCA  hFANCD2_exon10_R  CATTACTCCCAAGGCAATGAC 229 
 FA-D2, exon10, F GTCTGCCCAGCTCTGTTCAAAC FA-D2, exon10, R ATTACTCCCAAGGCAATGACTGACTG 232 
11 hFANCD2_exon11_F  GTGGGAAGATGGAGTAAGAGA  hFANCD2_exon11_R  AGCTCCATTCTCTCCTCTGAA  341 
 FA-D2, exon11, F CAGTTCAGTACAAAGTTGAGGTAGTG FA-D2, exon11, R CCGGATTAGTCAGTATTCTCAGTTAG 267 
12 hFANCD2_exon12_F  TGCCTACCCACTATGAATGAG  hFANCD2_exon12_R  TCTGACAGTGGGATGTCAGAA  211 
13 hFANCD2_exon13_F  CAGGAACTCCGATCTTGTAAG  hFANCD2_exon13_R  ATGTGTCCATCTGGCAACCAT  321 
 FA-D2, exon 13 F P1+2 CCGATCTTGTAAGTTCTTTTCTGGTACG FA-D2, exon 13 R P1+2 TGGCAACCATCAGCTATCATTTCCAC 302 
14 hFANCD2_exon14_F  CGTGTTTCGCTGATGTGTCAT  hFANCD2_exon14_R  TGGAGGGGGGAGAAAGAAAG  186 
15 hFANCD2_exon15a_F  GTGTTTGACCTGGTGATGCTT  hFANCD2_exon15a_R  GGAAGGCCAGTTTGTCAAAGT  325 
 hFANCD2_exon15b_F  GTGGAACAAATGAGCATTATCC  hFANCD2_exon15b_R  CTTATTTCTTAGCACCCTGTCAA  204 
 FA-D2, exon 15 F uniq GGAACAAATGAGCATTATCCATTCTGTG FA-D2, exon 15 R/ P1 CTCAATGGGTTTGAACAATGGACTG 363 
16 hFANCD2_exon16_F  AGGGAGGAGAAGTCTGACATT  hFANCD2_exon16_R  TTCCCCTTCAGTGAGTTCCAA 332 
 FA-D2, exon 16 F P1 GTCTGACATTCCAAAAGGATAAGCAAC FA-D2, exon 16 R CTTGAGACCCAGGTCAGAGTTC 344 
17 hFANCD2_exon17_F  GATGGGTTTGGGTTGATTGTG hFANCD2_exon17_R GATTAGCCTGTAGGTTAGGTAT  422 
 FA-D2, exon 17 F P1+2 CTGGCATATTCCTAAATCTCCTGAAG FA-D2, exon 17 R GCCTGTAGGTTAGGTATAAAGAAGTG 472 
18 hFANCD2_exon18_F  GGCTATCTATGTGTGTCTCTTT  hFANCD2_exon18_R  CCAGTCTAGGAGACAGAGCT  282 
19 hFANCD2_exon19_F CGATATCCATACCTTCTTTTGC  hFANCD2_exon19_R  ACGATTAGAAGGGAACATGGAA  328 
20 hFANCD2_exon20_F  CACACCAACATGGCACATGTA  hFANCD2_exon20_R TGACAGAGCGAGACTCTCTAA  239 
21 hFANCD2_exon21_F  AAAGGGGCGAGTGGAGTTTG  hFANCD2_exon21_R  GAGACAGGGTAGGGCAGAAA  339 
22 hFANCD2_exon22_F  ATGCACTCTCTCTTTTCTACTT  hFANCD2_exon22_R  GTAACTTCACCAGTGCAACCAA  279 
23 hFANCD2_exon23_F  TTCCCTGTAGCCTTGCGTATT  hFANCD2_exon23_R  ACAAGGAATCTGCCCCATTCT  356 
24 hFANCD2_exon24_F CTCCCTATGTACGTGGAGTAA  hFANCD2_exon24_R  CCCCACATACACCATGTATTG  258 
25 hFANCD2_exon25_F  AGGGGAAAGTAAATAGCAAGGA  hFANCD2_exon25_R  GTGGGACATAACAGCTAGAGA  350 
26 hFANCD2_exon26_F  GACATCTCTCAGCTCTGGATA  hFANCD2_exon26_R  TCAGGGATATTGGCCTGAGAT  324 
27 hFANCD2_exon27_F  GCATTCAGCCATGCTTGGTAA  hFANCD2_exon27_R  CCAATTACTGATGCCATGATAC  324 
28 hFANCD2_exon28_F  TCTACCTCTAGGCAGTTTCCA  hFANCD2_exon28_R  GATTACTCCAACGCCTAAGAG  354 
 FA-D2, exon 28 F TCTACCTCTAGGCAGTTTCCA FA-D2, exon 28 R GATTACTCCAACGCCTAAGAG 354 
29 hFANCD2_exon29_F  CTTGGGCTAGAGGAAGTTGTT  hFANCD2_exon29_R  TCTCCTCAGTGTCACAGTGTT  384 
30 hFANCD2_exon30_F  GAGTTCAAGGCTGGAATAGCT hFANCD2_exon30_R  TACCCAGTGACCCAAACACAA  348 
 FA-D2, exon 30 F CATGAAATGACTAGGACATTCCTG FA-D2, exon 30 F GCAAGATGAATATTGTCTGGCAATACG 319 
31 hFANCD2_exon31_F CCATTGCGAACCCTTAGTTTC  hFANCD2_exon31_R  ACCGTGATTCTCAGCAGCTAA  341 
32 hFANCD2_exon32_F  CCACCTGGAGAACATTCACAA  hFANCD2_exon32_R  AGTGCCTTGGTGACTGTCAAA  336 
33 hFANCD2_exon33_F  CACGCCCGACCTCTCAATTC  hFANCD2_exon33_R  TACTGAAAGACACCCAGGTTAT  340 
34 hFANCD2_exon34_F  TTGGGCACGTCATGTGGATTT hFANCD2_exon34_R  TATAGCAAGAGGGCCTATCCA  349 
 FA-D2, exon 34 II F GGCAATCTTCTTGGGCTTATTACTGAG FA-D2, exon 34 II R CAACTTCCAAGTAATCCAAAGTCCACTTC 327 
35 hFANCD2_exon35_F  TTAGACCGGGAACGTCTTAGT  hFANCD2_exon35_R  GTCCAGTCTCTGACAAACAAC  300 
36 hFANCD2_exon36_F  CCTCTGGTTCTGTTTTATACTG  hFANCD2_exon36_R  GGCCAAGTGGGTCTCAAAAC  398 
37 hFANCD2_exon37_F  CTTCCCAGGTAGTTCTAAGCA  hFANCD2_exon37_R  TCTGGGCAACAGAACAAGCAA  277 
 FA-D2, exon 37 II F CATCCTCTTACTAAGGACCCTAGTGAAAG FA-D2, exon 37 II R CAGCAACTTCCAAGTAATCCAAAGTCCAC 288 
38 hFANCD2_exon38_F  GCACTGGTTGCTACATCTAAG  hFANCD2_exon38_R  AAGCCAGGACACTTGGTTTCT  274 
39 hFANCD2_exon39_F  TGCTCAAAGGAGCAGATCTCA  hFANCD2_exon39_R  GCATCCATTGCCTTCCCTAAA  236 
40 hFANCD2_exon40_F  CCTTGGGCTGGATGAGACTA  hFANCD2_exon40_R  CAGTCCAATTTGGGGATCTCT  309 
41 hFANCD2_exon41_F  GATTGCAAGGGTATCTTGAATC  hFANCD2_exon41_R  CCCCAATAGCAACTGCAGATT  214 
42 hFANCD2_exon42_F  AACATACCGTTGGCCCATACT  hFANCD2_exon42_R  GCTTAGGTGACCTTCCTTACA  356 
43 hFANCD2_exon43a_F  GTGGCTCATGCTTGTAATCCT  hFANCD2_exon43a_R  AGCATGATCTCGGCTCACCA  366 
 hFANCD2_exon43b_F  CTGCCACCTTAGAGAACTGAA  hFANCD2_exon43b_R  TCAGTAGAGATGGGGTTTCAC  358 
 hFANCD2_exon43c_F  TAGAATCACTCCTGAGTATCTC  hFANCD2_exon43c_R  CTCAAGCAATCCTCCTACCTT  405 
 hFANCD2_exon43d_F  AGTTGGTGGAGCAGAACTTTG  hFANCD2_exon43d_R  CAGCTTCTGACTCTGTGCTTT  367 
 hFANCD2_exon43e_F  TCAACCTTCTCCCCTATTACC hFANCD2_exon43e_R  CTCGAGATACTCAGGAGTGAT  381 
 hFANCD2_exon43f_F  GGTATCCATGTTTGCTGTGTTT  hFANCD2_exon43f_R  AGTTCTGCTCCACCAACTTAG  306 
44 hFANCD2_exon44_F  CACCCAGAGCAGTAACCTAAA  hFANCD2_exon44_R  GAAAGGCAAACAGCGGATTTC  213 
 FA-D2, exon 44 II F CTAGGAGCTGTATTCCAGAGGTCAC FA-D2, exon 44 II R GGATCCTACCAGTAAGAAAGGCAAAC 250 
 
 
 
 
 
 
Supplementary Table S2C. FANCD2 mutation-specific primers 
 
 
 
PCR/ 
Sequencing 
Designation Sequence (5´→3´) 
PCR/Seq FA-D2, exon4-6 F GAAGGAAAACTATGGTAGGAAACTGGTG 
 FA-D2, exon 6 R CAGATGTATTAGGCTAATAAGCACAG 
 FA-D2, exon4-i6 R CCAGAAGCAGTTTGATGAGACTCTTAG 
 FA-D2, exon i4F GCTTTCCAAAAGAAGCTCTTTCAGAC 
 FA-D2, exon4-IVS F  GGAGACACCCTTCCTATCCCAAAG 
 FA-D2, exon 5F GAGTGGGCTAGAATGATTTTTAACAGC 
 FA-D2, exon 5 R CTCTGAGGAAAACAGAGCTTACAC 
 D2_AluYb9 F GCAATCTCGGCTCACTGCAAGCTC 
 D2_IVS4/AluYb9, R GCTGTTAAAAATCATTCTACTTTGGGAGG 
PCR/Seq FA-D2, ex 10 F GACTTGACCCAAACTTCCTATTGAA* 
 FA-D2, ex 14 F TCGTGTTTCGCTGATGTGT 
 FA-D2, ex 11 R CCGGATTAGTCAGTATTCTCAGTTAG 
 IVS14+2411 R CGAGACCATCCTGACTAACACG 
 IVS14+2512 R GATACCCCTTAAGAATACAGAGC 
PCR/Seq FANCD2_16S AGAGCTAGGGAGGAGAAGTCTGA 
 FANCD2_18A GAGCTGAGATCGTGCCAACT 
 FANCD2_17S TGGTCAAGTTACACTGGCATATT 
 FANCD2_17A CCATCCTTCAGCAATCACTC 
PCR/Seq D2_P2_21_23 F GTTTTCTGATACTTGGAAACTACTGGCTTG 
 D2_P1_21_23 R GACACAGAGGTAGCAAAGGATGTTC 
Seq FA-D2, ex21_23, int1 CTATGATGAATTTGCCAACCTGATCC 
 FA-D2, ex21_23, int2 GAGGGCTCCTTCACTTAATAACAATC 
 FA-D2, ex21_23, int3 GTATTGTTTACCTGCTGGCTGGTTG 
PCR FA-D2_sup_exon26 II F uniq TAGGGTCACAAGCCTAATCTCCTTT 
 FA-D2_sup_exon26 II R uniq GGCCATGATGAATAATCTTTCTTTTGTTTG 
  
Supplementary Table S3. Microsatellite primers 
 
STR Genomic Position 
[Mb] 
Sense Primer Sequence (5´→3´) Antisense Primer Sequence (5´→3´) 
D3S1597 9,34 AGTACAAATACACACAAATGTCTC CAATTCGCAAATCGTTCATTGCT 
D3S1038  10,49 AAAGGGGTTCAGGAAACCTG CCCTCCAGTAAGAGGCTTCCTAG 
D3S3611 10,53 GCTACCTCTGCTGAGCATATTC CACATAGCAAGACTGTTGGGGGC 
D3S1675 10,64 GGATAGATGGATGAATGGATGGC CCTCTCTAACTACCAATTCATCCA 
 
Supplementary Table S4. Laboratory diagnostic data of the 29 cohort FA-D2 patients 
 
 
Patient 
number 
Kindred
Sibling
Cell type of 
lab 
diagnosis 
G2-phase arrest, 
G2/GF 
 
Spon         MMC/DEB 
Breaks/cell 
 
Spon         MMC/DEB
Technique of 
complementation 
group 
assignment 
FANCD2 mutation 
 
Allele 1                                     Allele 2 
Somatic 
mosaicism 
1 1 / I Lymphocyte 65.7% n.d. 0.07 4.5 (M) 
[6.6 (M)] 
IB of LCL c.696−121C>G  
(exonization) 
c.696−121C>G 
(exonization) 
None 
(residual 
protein) 
2 2 / I Lymphocyte 54.3% 70.1% (M) 0.09 1.4 (M),
1.5 (D) 
IB and RC of LCL c.1948−6C>A  
(exon 22 skipping) 
c.3599delT None 
(residual 
protein) 
3 3 / I Lymphocyte 
(prior to 
mosaicism) 
38.6% 
(prior to 
mosaicism) 
46.6% (M) 
(prior to 
mosaicism)
0.04 0.06 (M) RC of fibroblasts c.1948−16T>G  
(exon 22 skipping) 
c.1948−16T>G  
(exon 22 skipping) 
1954G>A 
(exon 22), 
V652I, 
reconstitutes 
exon 22 
recognition 
(blood, BM, 
LCL) 
4 4 / I Lymphocyte 45.7% 63.6% (M) n.d. n.d. RC of fibroblasts c.1948−16T>G 
 (exon 22 skipping) 
c.1948−16T>G  
(exon 22 skipping) 
None 
(no LCL) 
5 4 / II Lymphocyte 44.5% 58.9% (M) n.d. n.d. RC of fibroblasts c.1948−16T>G 
 (exon 22 skipping) 
c.1948−16T>G 
 (exon 22 skipping) 
None 
(residual 
protein) 
6 5 / I Lymphocyte 34.5% 64.7% (M) 0.05 4.7 (M) 
5.6 (D) 
IB and RC of LCL c.274−57_−56insinvAluYb8nt36_319
+dup c.274−69_−57  
(exon 5 skipping) 
c.3803G>A 
 
None 
(residual 
protein) 
7 6 / I Lymphocyte 34.8% 51.5% (M) n.d. n.d. IB of LCL c.904C>T 
 
c.1092G>A 
 
None 
(residual 
protein) 
8 7 / I Lymphocyte 45.6% 58.4 (M) 0.06 1.3 (M) IB of LCL c.990−1G>A 
 (aberrant splicing) 
c.1948−6C>A  
(exon 22 skipping) 
None 
(residual 
protein) 
9 8 / I Lymphocyte 65.3% 70.9% (M) 0.12 n.d. IB of LCL c.810_812delGTC c.1948−16T>G  
(exon 22 skipping) 
None 
(residual 
protein) 
 
Patient 
number 
Kindred
Sibling
Cell type of 
lab 
diagnosis 
G2-phase arrest, 
G2/GF 
 
Spon          MMC/DEB 
Breaks/cell 
 
Spon         MMC/DEB
Technique of 
complementation 
group 
assignment 
FANCD2 mutation 
 
Allele 1                                  Allele 2 
Somatic 
mosaicism 
10 9 / I Lymphocyte 38.4% 58.4% (M) n.d. n.d. RC of fibroblasts c.1948−16T>G  
(exon 22 skipping) 
c.2715+1G>A 
(aberrant splicing) 
None 
(residual 
protein) 
11 10 / I Lymphocyte 55.4% 65.8% (M) ? (Wien) ? (Wien) IB of LCL c.3707G>A 
(aberrant splicing) 
c.2835dupC 
 
None 
(residual 
protein) 
12 11 / I  Lymphocyte 40.2% 61.1% (M) n.d. n.d. IB of LCL c.274−57_−56insinvAlu 
Yb8nt36_319 
+dup c.274−69_−57 
c.3453_3456delCAAA  None 
(residual 
protein) 
13 12 / I Lymphocyte 27.6% 57.8% 0.11 1.08 (M)
2.9 (D) 
IB of LCL c.1948−16T>G 
(exon 22 skipping) 
c.1948−16T>G  
(exon 22 skipping) 
None 
(residual 
protein in T 
cells and LCL) 
14 13 / I Lymphocyte 
Fibroblast 
20.9% 32.1% (M) n.d. n.d. Mutation analysis 
(by sibling) 
c.1948−6C>A  
(exon 22 skipping) 
2775_2776CC>TT 2775_2776 
CC (blood, 
LCL) 
15 13 / II Lymphocyte 
 
Fibroblast 
25.0% 35.4% (M)
 
69.2% (M)
0 0.11 (M)
0.02 (D) 
RC of fibroblasts c.1948−6C>A  
(exon 22 skipping) 
2775_2776CC>TT Recombination 
16 14 / I Lymphocyte n.d. n.d. 0.04 1.78 (D) IB of LCL c.2444G>A c.2444G>A None 
(residual 
protein) 
17 14 / II Lymphocyte n.d. n.d. 0.12 3.1 (D) Mutation analysis 
(by sibling) 
c.2444G>A c.2444G>A None 
(no LCL) 
18 15 / I Lymphocyte n.d. n.d. 0.12 1.5 (D) IB of LCL c.696−2A>T 
(exon 10 skipping) 
c.1321_1322delAG  
(aberrant splicing) 
None 
(residual 
protein) 
19 16 / I Fetal blood n.d. n.d. n.d. 3.7 (D) RC of fetal 
fibroblasts 
c.692T>Gpat c.2444G>Amat not done 
20 17 / I Lymphocyte n.d. n.d. 0.02 8.4 (D) IB and RC of LCL c.1948−6C>Amat, 
 (exon 22 skipping)  
2660delApat None 
(residual 
protein) 
21 18 / I Lymphocyte n.d. n.d. 0.02 5.4 (D) 
10.3 (D) 
IB of LCL c.2404C>T c.2444G>A None 
(residual 
protein) 
 
Patient 
number 
Kindred
Sibling
Cell type of 
lab 
diagnosis 
G2-phase arrest, 
G2/GF 
 
Spon          MMC/DEB 
Breaks/cell 
 
Spon         MMC/DEB
Technique of 
complementation 
group 
assignment 
FANCD2 mutation 
 
Allele 1                                       Allele 2 
Somatic 
mosaicism 
22 19 / I Lymphocyte n.d. n.d. 0.04 3.7 (D) RC of fetal 
fibroblasts from 
880/2 (early 
spontaneous 
abortion) 
c.2444G>Apat c.2715+1G>Amat 
 (aberrant splicing) 
None 
(residual 
protein) 
23 20 / I Lymphocyte n.d. n.d. 0.08 7.4 (D) IB of LCL c.757C>T c.1367T>G None 
(residual 
protein) 
24 20 / II Lymphocyte n.d. n.d. 0.20 8.9 (D) IB of LCL c.757C>T  c.1367T>G None 
(residual 
protein) 
25 21 Lymphocyte n.d. n.d. Data 
missing 
Data 
missing 
Mutation analysis c.1948−16T>G  
(exon 22 skipping) 
c.1948−16T>G  
(exon 22 skipping) 
1953G>T 
(W651C) 
(blood, LCL) 
26 22 / I Fibroblast 22.2% 
(fibroblast) 
54% 
(fibroblast, 
300 nM ≈ 
100 ng/ml 
MMC) 
0.04 0.16 
(300 nM ≈ 
100 ng/ml 
MMC) 
Mutation analysis 
in fibroblasts 
(by sibling) 
c.376A>G 
 (aberrant splicing) 
c.3803G>A 376A (blood,) 
27 22 / II Lymphocyte n.d. n.d. 0.12 >10 (M) IB and IP of LCL c.376A>G 
 (aberrant splicing) 
c.3803G>A None 
(residual 
protein) 
28 23 / I Lymphocyte n.d. n.d. 0.10 6.0 (M) IB, IP and RC of 
LCL 
c.206−2A>T  
(exon 4 skipping) 
g.22875_23333del459 
(c.1414−71_c.1545+256del459) 
None 
(residual 
protein) 
29 23 / II Lymphocyte n.d. n.d. 0.12 8.1 (M) Mutation analysis 
(by sibling) 
c.206−2A>T  
(exon 4 skipping) 
g.22875_23333del459 
(c.1414−71_c.1545+256del459) 
None 
(residual 
protein) 
MMC, M, mitomycin C; DEB, D, diepoxybutane; RC, retroviral complementation; IB, immunoblotting; IP, immunoprecipitation; LCL lymphoblast cell line; n.d., not determined; G2, 
G2 phase fraction of the cell cycle; GF, growth fraction; G2/GF, ration G2 phase fraction over GF 
 
Supplementary Table S5. Clinical diagnostic data of the 29 cohort FA-D2 patients 
 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
1 1 / I unkown 
f 
Asian 
Indian 
6 mo IUGR, patent ductus 
arteriosus, pigmentation 
anomalies, microcephaly, 
low-set ears, hypoplastic 
thumb with duplicate nail (R), 
radial ray aplasia with 
cutaneous thumb (L), pelvic 
kidney (R), congenital hip 
dislocation (L), aplasia of the 
corpus callosum 
BMF as of 2 y 4mo, 
transfusions from 3 y 2 mo, 
AML at 7.0 y 
† 7 y 6 mo (AML, 
pneumonia) 
No SABs; no 
known cancer 
2 2 / I absent 
f 
Caucasian
German 
5 y 7 mo GR, pigmentation anomalies, 
microcephaly, microphtalmia, 
low-set thumbs, duplicate 
kidney (R), dysplastic hips 
BMF as of 5 y 7 mo, cortisol 
from 8 y, transfusions from 8 y 
4 mo, androgen from 9 y 2 mo
† 11 y 4 mo 
(subarachnoidic 
hemorrhage) 
1 SAB; 
MGM:Cervix ca, 
40 y 
 
3 3 / I cousins of 1st° 
m 
Caucasian
Turkish 
1 y 11 mo IUGR, pigmentation 
anomalies, microcephaly, 
hypoplastic thumbs (L>R), 
syndactyly II/III toes, 
hypogenitalism, 
glomerulosclerosis 
Stable partial mosaïcism, BMF 
as of 11 y, cortisol and 
androgen from 12 y, 
transfusions from 18 y 9 mo, 
BMT at 19 y 7 mo 
† 20 y 7 mo 
(viral encephalitis 
following BMT) 
No SABs, no 
known cancer 
4 4 / I cousins of 2nd° 
f 
Caucasian
Turkish 
5 y 10 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia, hypoplastic 
thumb (R), hydocephalus 
internus, hypoplastic corpus 
callosum, mental retardation, 
hyperactivity attention deficit 
disorder 
BMF as of 2 y 6 mo, 
transfusions from 2 y 6 mo, 
subdural hemorrhage 6 y, BMT 
at 7 y 
8 y 3 mo No SABs; no 
known cancer 
5 4 / II cousins of 2nd° 
m 
Caucasian
Turkish 
4 y 5 mo IUGR, microcephaly, 
microphtalmia, strabism, 
mental retardation, 
hyperactivity attention deficit 
disorder 
BMF as of 3 y 3 mo, 
transfusions from 3 y 3 mo, 
oxymetholon from 5y 9 mo 
6 y 11 mo No SABs; no 
known cancer 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
6 5 / I absent 
m 
Caucasian
German 
2 y 6 mo GR, microcephaly, micro-
phtalmia, absent anthelix 
(R), radial ray hypoplasia, 
preaxial hexadactyly (R), 
duplicate pelvic kidney (R), 
maldescensus of the testes, 
micropenis, dysplastic hips, 
hypoplastic corpus callosum, 
misshaped brain ventricles, 
psychomotor retardation 
BMF as of 2 y 9 mo,  
BMT at 3 y 3 mo. 
4 y 4 mo No SABs; 
PGM cancer 70 
y, otherwise no 
cancer history 
7 6 / I absent 
f 
Caucasian
Italian 
2 y IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia, absent 
thumbs, short radii, absent 
anthelix (R), closed auditory 
canals 
BMF as of 4.5 y 12 y No SABs; no 
cancer history 
8 7 / I absent 
m 
Caucasian
German 
3 y 9 mo Pigmentation anomalies, 
microcephaly, ‘flat’ auricles-
absent anthelix?, ptosis, 
short thumbs, hyperactivity 
attention deficit disorder 
BMF as of 4 y 4 y 4 mo No SABs; no 
cancer history 
9 8 / I absent 
f 
Caucasian
Czech 
2 y 11 mo IUGR, microcephaly, brain 
atrophy, patent ductus 
arteriosus, esophagus 
atresy, tracheoesophageal 
fistula (IIIb), hypoplastic 
kidneys, polycystic ovary (L), 
triphangeal digitalized 
thumbs, pedes equinovari, 
rib anomaly (VACTERL-like 
association) 
BMF as of 2 y 10 mo, 
transfusions from 2 y 11mo 
† 5 y 10 mo 
(hemorrhage) 
1 SAB (first 
trimester); 
no cancer in the 
family 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
10 9 / I absent 
f 
Caucasian
Turkish 
7 mo IUGR, pigmentation 
anomalies, microcephaly, 
hydrocephalus internus, 
absent corpus callosum, 
microphtalmia, small mouth, 
low-set ears, hypoplastic 
thumbs, unilateral 
triphalangeal (R), pelvic 
kidney (L), hip luxation, 
psychomotor retardation 
BMF as of 2 y 2 y 3 mo 1 SAB (first 
trimester); 1 
pregnancy 
terminated 
because of 
hydrocephalus 
and renal 
agenesy; PGF 
bronchus ca 
11 10 / I absent 
f 
Caucasian
Austrian 
10 y 10 mo IUGR, pigmentation 
anomalies, microcephaly, 
hypoplastic thumbs, ectopic 
kidney (R) 
BMF as of 10 y 10 mo, 
transfusions from 10 y 10 mo, 
MDS (RAEB-t) with del(7)(q32) 
at 10 y 10 mo, BMT at 11y 1 
mo 
11y 11 mo No SABs; no 
cancer history 
12 11 / I absent 
m 
Caucasian
Danish 
3 mo IUGR, atresy of the 
duodenum, microcephaly, 
dilated lateral ventricles and 
stenosis of the aquaeduct 
(hydrocephalus), hypoplasia 
of the carpous callosum, 
microphtalmia, closed 
auditory channels, 
hypoplastic thumbs, 
micropenis 
BMF as of 2 wks 5 mo No SABs; PGM 
and MPGM 
breast ca., 
MGGF prostate 
ca. 
13 12 / I cousins of 1st° 
m 
Caucasian
Turkish 
5 y 5 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphalmia, psychomotor 
retardation, Michelin tire 
baby syndrome 
BMF as of 1 y 5 mo 5 y 8 mo No SABs; 
no cancer 
history 
14 13 / I absent 
f 
Caucasian
German 
34 y 2 mo IUGR, microcephaly, mild 
radial ray hypoplasia 
None 34 y No SABs; no 
cancer history 
15 13 / II absent 
f 
Caucasian
German 
21 y 11 mo IUGR, microcephaly, radial 
ray hypoplasia, dysplasia of 
mandibula, anomalies of the 
teeth, dysplasia of hip (R), 
mental retardation 
Transfusions from 17 y 6 mo, 
MDS(RARS-RAEB) 
 at 17 y 6 mo 
† 23 y 5 mo 
(pneumonia, 
invasive 
aspergillosis, 
hemorrhage) 
No SABs; no 
cancer history 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
16 14 / I cousins of 3° 
m 
Caucasian
Spanish 
6 y Patent ductus arteriosus, 
pigmentation anomalies, bifid 
thumb (R), hypogonadism 
BMF as of 7 y (very mild 
hypoplasia of the myeloid 
series) 
25 y No SABs; 
MGF lung, 
PGFstomach ca. 
17 14 / II cousins of 3° 
m 
Caucasian
Spanish 
8 mo Pigmentation anomalies, 
microphtalmia, hypoplastic 
thumb (R), absent os 
metacarpale I (L), glandular 
hypospadia 
Blood cell counts at low-range 
normal levels 
20 y No SABs; 
MGF lung,  
PGF stomach 
ca. 
18 15 / I absent 
f 
Caucasian
Spanish 
5 y 3 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia, hypotelorism, 
annular pancreas 
BMF as of 5 y 3 mo, androgen, 
G-SCF, EPO and transfusions 
from 5 y 3 mo, BMT at 10 y 11 
mo 
† 11 y 1 mo 
(graft failure / no 
take) 
No SABs; 
MMGM colon 
ca. 
19 16 / I absent 
m 
Caucasian,
maternal 
Irish and 
English, 
paternal 
Irish and 
Italian 
22 wk of gestation IUGR, absent thumb and 
radial aplasia (R), lateral 
cerebral ventricular dilation 
(hydrocephalus) 
N/A N/A, terminated 
with diagnosis of 
FA 
3 first trimester 
SABs, 4th fetus 
with IUGR, 
radial aplasia, 
cystic hygromas, 
encephalocele, 
probably heart 
defects, 
terminated; 
MGM pancreas, 
MMGM breast, 
MGF melanoma 
& basal cell ca. 
20 17 / I absent 
m 
Caucasian
maternal 
German, 
paternal 
Dutch 
4 y 5 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia 
BMF as of 2 y, 
BMT at 5 y 
9 y 
(4y post BMT) 
1 SAB, M.3x 
basal cell, 
MMMGM 
melanoma, 
MMGF breast, 
PGM bowel ca. 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
21 18 / I absent 
m 
Caucasian
Hispanic 
(Mexican) 
7 mo IUGR, café au lait spots, 
microcephaly, micro-
phtalmia, hearing loss 
(auditory canals? sensory 
hearing impairment?), 
absent thumbs and radii, 
intestinal atresia, renal 
defects, genital anormalities 
(undescended testes), 
learning disabilities 
None yet 10 y 3 mo No SAB; 
one cancer; 
22 19 / I absent 
m 
Caucasian
maternal 
Irish, Dutch 
Yugoslavian 
French and 
Native 
American, 
paternal 
Irish and 
Sicilian 
Newborn Patent ductus arteriosus, 
pigmentation anomalies, low-
set ears, malformed auricle 
(R), constriction bands of 
mid forearms (Michelin tire 
baby syndrome?), preaxial 
hexadactyly (R), hypoplastic 
thumb with ponce flottant (L) 
BMF as of 1 y 4 mo 2 y 6 mo 5 miscarriages 
with one positive 
for FA; PGM 
breast, MPGM 
cervix and lung 
ca., MMGM 
brain tumor 
23 20 / I absent 
m 
maternal 
African 
American / 
Caucasian,
paternal 
African 
American 
(1 mo) IUGR; microcephaly; 
microphtalmia; hypoplastic 
thumb (L); hypoplastic 
metacarpal I (R); horseshoe 
kidney 
none 1 y 4 mo GM: 2 
miscarriages. 
Cancer only  in 
GreatGP 
generation 
24 20 / II absent 
f 
maternal 
African 
American / 
Caucasian,
paternal 
African 
American 
4 y 6 mo IUGR; café-au-lait spots; 
microcephaly; microphtalmia 
BMF starting from 4 y 6 mo 5 y 9 mo GM: 2 
miscarriages 
Cancer only  in 
GreatGP 
generation 
25 21 / I cousins of 1st° 
m 
Caucasian
Turkish 
5 y 5 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia, pelvic kidney 
BMF starting from 4 y; 
oxymethalone and prednisone 
from 5 y 5 mo 
† 9 y (intracranial 
hemorrhage) 
No SAB; no 
cancer history 
Patient 
number 
Kindred/
Sibling 
Consanguinity 
Gender 
Ethnicity 
Nationality Age at diagnosis Clinical presentation Hematologic manifestations 
Survival at last
follow-up Family history  
26 22 / I absent 
f 
Caucasian
Dutch 
5 y IUGR (asymmetrical); 
pigmentation anomalies; 
microcephaly; ventriculo-
megaly (hydrocephalus) and 
multiple developmental 
anomalies of the brain, 
possibly holopros-encephaly; 
hypotelorism; microphtalmia; 
narrow auditory canals; 
hypoplastic os metacarpale I, 
renal aplasia (R); dysplasia 
of the hip (L); growth hormon 
deficiency  
BMF as of 5 y; transfusions 
from 6 y 9 mo + GCSF; BMT at 
7 y 10 mo 
9 y No SAB; 
no cancer 
history 
27 22 / II absent 
m 
Caucasian
Dutch 
3 y IUGR; pigmentation 
anomalies; microcephaly; 
hypoplastic corpus callosum; 
hypertelorism; 
blepharophimosis; preaxial 
hexadactyly (L) 
BMF as of 2 y 1 mo; 
transfusions from 5 y 8 mo; 
BMT at 7 y 7 mo 
7 y 9 mo No SAB; 
no cancer 
history 
28 23 / I absent 
m 
Caucasian
Dutch 
8 y 6 mo IUGR, pigmentation 
anomalies, microcephaly, 
Kartagener syndrome with 
situs inversus, mild mental 
retardation 
BMF as of 8 y 5 mo; no 
transfusions; BMT at 9 y 5 mo 
† 10 y 1 mo 
(gastro-intestinal 
hemorrhage due 
to necrotizing 
enterocolitis post 
BMT) 
1 SAB;  
no cancer 
history 
29 23 / II absent 
m 
Caucasian
Dutch 
5 y 8 mo IUGR, pigmentation 
anomalies, microcephaly, 
microphtalmia 
BMF as of 5 y 8 mo; 
BMT at 6 y 7 mo 
7 y 10 mo 1 SAB;  
no cancer 
history 
f, female; m, male; L, left; R, right; (IU)GR, (intrauterine) growth retardation; BMF, bone marrow failure; BMT, bone marrow transplantation; MDS, myelodysplastic syndrome; AML, 
acute myelogenous leukemia; SAB, spontaneous abortion 
 
Supplementary Table S6A. FANCD2 splice acceptor calculations  
 
 3´Splice site (acceptor) 
Exon  Wild type/ 
variant 
Sequence Score 
(Maxent*) 
 4 Consensus ctcttcttttttctgcatagCTG  9.12 
 IVS3-2A>T ctcttcttttttctgcattgCTG  0.76 
 10 Consensus tctttttctaccattcacagTGA  7.39 
 IVS9-2A>T tctttttctaccattcactgTGA  -0.97 
 13 Consensus ttcctctctgctacttgtagTTC  6.19 
 IVS12-1G>A ttcctctctgctacttgtatTTC  -2.56 
 22 Consensus tgtttgtttgcttcctgaagGAA  6.43 
 IVS21-16T>G tgttggtttgcttcctgaagGAA  5.58 
 IVS21-6C>A tgtttgtttgcttcatgaagGAA  4.51 
37a Ex37 (consensus) ACTTTTGTTGTTTTCTTCCGTGT  2.10 
 3706C>A ACTTTTGTTGTTTTCTTCAGTGT  10.14 
 
 
 
 
 
 
 
 
 
 
* MaxEntScan::score3ss for human 3' splice sites  
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html) 
 
 
 
Supplementary Table S6B. FANCD2 splice donor calculations 
 
 
 
 
 
 
 
 
 
 
 
5´Splice site (donor) 
Exon Wild type/ 
variant 
Sequence Score (splicefinder*) Difference Result 
 5 Consensus CAGgtgtggag LC4 12||3|2|   
 376A>G CGGgtgtggag LC2 2|8||3|2  large malfunction 
 9a IVS (consensus) acggtaactta LC4  ||12|2||   
  IVS9-121C>G ACGgtaagtta HC3 ||17|| large gain of function 
 10 Consensus AAGgtagaaaa LC4  |12|||2|   
 782A>T ATGgtagaaaa LC3 ||10|||2| small malfunction 
* Splicefinder (http://www.uni-duesseldorf.de/rna/html/5__ss_mutation_assessment.php) 
 
Supplementary Figure S1. Circular map of the vector S11FD2IN. The retroviral 
expression vector S11FD2IN contains a bicistronic construct of the full-length 
FANCD2 cDNA (FANCD2) and the neomycin resistance gene (NEO). Translation of 
the latter is ensured by an internal ribosomal entry site (IRES). Shown are also the 
LTRs, the restriction sites and their positions and the bacterial resistance (AmpR). 
 
